A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose-Ranging Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared with Placebo for the Treatment of Patients with Mycobacterium avium Compl

Principal Investigator

Elizabeth Talbot

Study Number

STUDY02001722

Summary

The purpose of the study is to evaluate The microbiological response and clinical efficacy of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD). The safety and tolerability of SPR720 in a participants population with NTM- PD The pharmacokinetic (PK) of SPR719, active moiety, following orally (po) administered prodrug SPR720 in a participant population with NTM-PD.

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms